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Organisms that are normally sensitive to the action of an antibiotic may sometimes develop resistance 
or insensitivity to it. This, they may do through destroying the antibiotic or by retaining their growth 
even in the presence of the drug. Microbial resistance to antibiotics is now widespread and poses a 
serious clinical threat. Microorganisms develop resistance to antibiotics by any of the following 
mechanisms:  selection, mutation, phage transduction, and transference while microbial resistance can 
either be inherent in the organism or acquired through the environment. Factors that have led to the 
continued occurrence of bacterial resistance to antimicrobial agents include: over prescription of 
antibiotics, use of under dose, prescribers’ irrational attitudes, patients’ demands, inappropriate 
advertisements and use of antibiotics in agriculture. Microbial resistance to antibiotics can thus be 
minimized through proper enlightenment, more rational antibiotic selection during treatment and proper 
legislation. 
 





Antibiotics are organic substances produced by 
microorganisms and capable at low concentration of 
inhibiting the growth of, or destroying another 
microorganism (Ibezim, 2005). These drugs have been 
isolated from numerous sources but principally from 
bacteria (tetracyclines, bacitracin, polymyxin, chloram-
phenicol, streptomycin) and fungi (cephalosporins, 
penicillins). Penicillin was the first antibiotic discovered 
by Sir Alexander Flemming in 1928. With industrialization 
however, came the revolutionary development of many 
more antibiotics. Since then, the use of antibiotics has 
steadily increased both in human treatment and animal 
disease management (McKeon, et al, 1995). 
Soon after the introduction of the penicillins into clinical 
practice, the fact that the development of antibiotic 
resistance would be a problem became apparent. The 
increased use of antibiotics in man and animals and the 
extension of uses to areas other than prophylaxis and 
treatment of diseases have helped to create serious 
problems. Bacterial resistance to antibiotics has thus 
been recognised since the first drugs were introduced for 
clinical use. 
Bacterial resistance to antibiotics refers to the 
insensitivity of bacteria to the antimicrobial actions of a 
given antibiotic. The organism in question may develop 
the ability to destroy the antibiotic or to grow in its 
presence. Example of the former type are penicillin-
inactivating staphylococci and chloramphenicol-
acetylating staphylococci (British Pharmaceutical Codex, 
1979).  
Sulphonamides were introduced in 1935 and about ten 
years later, 20% of clinical isolates of Neisseria 
gonorrhoea had become resistant to them. Resistance to 
penicillin in some strains of Staphylococcus was 
recognized almost immediately after introduction of the 
drugs. Resistance to penicillin today occurs in as many 
as 80% of all strains of Staphylococcus aureus (Bryan, 
1989). More and more strains of organisms have 
become resistant to the available antibiotics. 
In the late 1940s and early 1950s, the discovery and 
introduction of streptomycin, tetracycline and 
chloramphenicol made the age of antibiotic 
chemotherapy come into full being. These antibiotics 
were effective against Gram positive and Gram-negative 
bacteria, tuberculosis bacilli and intracellular parasites. 
By 1953 however, during a Shigella outbreak in Japan, a 
strain of the dysentery bacillus was isolated which had 
multiple resistance exhibiting resistance to 
chloramphenicol, streptomycin, sulphonamides and 
tetracyclines. There was evidence to support the fact that 
the bacteria could pass genes for multiple drug 
resistance between strains and even between species. It 
was also apparent that Mycobacterium  tuberculosis  was 






cin, which has become a main stay in tuberculosis 
therapy. 
It is noteworthy that antibiotic resistance can be single 
or multiple. Multidrug resistant tuberculosis is no longer 
confined to any one country or to those co-infected with 
Human Immune Deficiency Virus (HIV), but has 
appeared in locations as diverse as Africa, Asia and 
Eastern Europe, among health care workers and in the 
general population (Essential Drug Monitor, 2000). 
An increased incidence of resistant organisms in a 
population exposed to an agent that affects growth and 
reproduction can be attributed to the survival and 
proliferation of a small fraction of the original population. 
The resistant survivors are genetically, structurally, 
behaviourally and physiologically different from the 
majority. When antibiotics are introduced, they will surely 
have this effect because by creating a hostile 
environment for susceptible pathogen population, they 
encourage the selective survival and multiplication of 
forms against which the antibiotics has little or no effect. 
This caused serious concern because it seemed possible 
that each new antibiotic will loose its usefulness as 
pathogenic organisms become resistant to them. This 
necessitated the research into the mode of action of 
antibiotics and the mechanisms by which their effects are 
circumvented by resistant organisms. 
Most of the microorganisms producing antibiotics are 
resistant to the action of their own antibiotics. Although 
they are affected by other antibiotics, their antibiotics are 
effective against closely related strains. It was stipulated 
that these antibiotics afford them some nutritional 
advantage in their habitat by inhibiting or antagonizing 
other organism or they act as some sort of hormone or 
signal molecule associated with sporulation, dormancy or 
germination. The maintenance of a substantial 
component of the bacterial genome devoted solely to 
synthesis of antibiotics leads to the conclusion that the 
process or molecule is very important if not essential to 
the survival of these organisms in their natural habitat, 
because antibiotics are rather large, complicated organic 
molecules and may require as many as 30 separate 
enzymatic steps to synthesize. 
Bacteria may be inherently or naturally resistant to an 
antibiotic when inherent properties of the bacterium are 
responsible for preventing antibiotic action (Godfrey et 
al., 1984).  Inherent resistance is therefore that, 
possessed inherently by bacteria. For example, some 
bacteria are more resistant to certain antibiotics than 
others. For instance, Gram-negative bacteria are 
inherently resistant to a number of antibiotics such as 
vancomycin and fusidic acid, which are highly effective 
against Gram-positive organisms like streptococci and 
staphylococci (Franklin, 1992). Within the Gram-negative 
group, Pseudomonas aeruginosa presents especially 
intractable chemotherapeutic problem as it has unusually 
high intrinsic resistance to many antibiotics. This inherent 
resistance seems to be associated with the permeability  




of the complex outer layers of the cell envelope to some 
drugs, which prevents the attainment of an inhibitory 
concentration within the cell. The non-specific resistance 
of Gram-negative bacteria is recognized as a limitation in 
the treatment of infections of these organisms. However, 
the general pattern of resistance is well known and 
stable, so that drugs are prescribed of which the infecting 
organism are not inherently resistant (Franklin, 1992). 
The ability of Gram-negative bacteria to be resistant to 
antibiotics active against most Gram-positives is 
associated with the outer cell layer like the outer 
membrane, which is absent in Gram-positive organisms. 
This outer membrane establishes a permeability barrier 
against antibiotics. An organism may lack the transport 
system for the antibiotics or lack the target sites or the 
reaction that is targeted by the antibiotics. 
Bacteria can develop resistance to antibiotics usually 
but not always after exposure to the antibiotics. This type 
of resistance results from changes in the bacterial 
genome. In bacteria, acquired resistance is driven by two 
genetic processes, which are mutation and selection that 
is sometimes referred to as vertical evolution and 
exchange of genes between strains and species also 
called horizontal evolution. In other words, acquired 
immunity is a type of immunity acquired by the 
microorganisms in response to environmental and other 
changes. For instance, when a new antibiotic is 
introduced into clinical practice, for treating infections 
resulting from bacteria not inherently resistant to it, the 
drug would be quite effective. After some time however, 
treatment failures may result with the same drug on the 
same infection due to this newly acquired resistance of 
the drug by the infecting organism. The time before 
emergence of the resistance and the rate of emergence 
may not be predictable. Resistance of Staphylococci, for 
instance, to neomycin did not appear until after nine 
years of its introduction (Franklin, 1992). 
Natural resistance is always chromosomally mediated 
while acquired resistance may be by mutations in the 
chromosome or acquisition of gene coding for resistance 
from an external source usually through a plasmid or 
transpon. Acquired and natural resistances are clinically 
important and can cause treatment failure. Acquired 
resistance is however, the major threat in the spread of 
antibiotic resistance (Russel, 1996). 
Bacteria are able to exchange genes in nature by three 
processes – conjugation, transduction and 
transformation. Conjugation involves cell-to-cell contact 
as DNA crosses a sex pillus from donor to recipient. 
Plasmids that can mediate their own transfer are called 
conjugative plasmids. Gram positive and Gram-negative 
bacteria can conjugate. During transduction, a virus 
transfers the gene between mating bacteria. DNA is 
acquired directly from the environment having been 
released from another cell during transformation. The 
numbers of bacteria that can undergo transformation are 
limited  e.g. Neisseria  gonorrhoea can  naturally  acquire  
 




DNA from their own species, so are selective in their 
acquisition of DNA from the environment (Scholer et al., 
1984). 
Genetic recombination can follow the transfer of DNA 
from one cell to another leading to the rates of adaptation 
and evolution that can be observed in the bacteria. For 
these reasons, bacterial resistance to the antibiotic 
environment seems to take place very rapidly in 
evolutionary time. 
Treatment failure in bacterial infectious diseases is 
commonly caused by bacterial resistance (Tenover et al., 
1996a, b). Obviously, if a pathogen is able to develop or 
acquire resistance to an antibiotic, then that substance 
becomes useless in the treatment of infectious diseases 
caused by that pathogen unless the resistance can 
somehow be overcome with secondary measures. An 
antibiotic resistant bacterial infection leads to the use of 
more expensive and often more toxic drugs. So as 
pathogens develop resistance, we must find different 
antibiotics to fill the place of the old ones in treatment 
regimes. Natural penicillins, for instance, have become 
useless against staphylococci and must be replaced by 
other antibiotics (Sabath, 1982).  
Tetracycline has been so widely used and misused for 
decades and has become worthless for many of the 
infections that once designated it as a ‘wonder drug’. The 
emergence of vancomycin resistant enterococci (VRE) 
has caused great concern because vancomycin is often 
the only effective antibiotic against methicillin resistant 
Staphylococcus aureus (MRSA) strains. So when 
methicillin resistant S. aureus acquires resistance to 
vancomycin, it will leave us with serious pathogens 
untreatable with any existing antibiotics. In no distant 
time, resistance of methicillin resistant S. aureus to 
vancomycin will be clinically possible because the 
transfer of vancomycin resistance from VRE to methicillin 
resistant S. aureus has been demonstrated in the 
laboratory (Saravolatz, 1982). There is also a problem in 
finding new antibiotics to fight new diseases. In the past 
two decades, many new bacterial infections have been 
discovered – Lyme disease, toxic shock syndrome, 




MECHANISMS OF BACTERIAL RESISTANCE TO 
ANTIBIOTICS 
 
Bacterial cells may develop resistance to given 





Resistant organisms may become apparent as a result of 
the  destruction  of  sensitive  strains   by   the   antibiotic, 





For example, penicillin therapy destroys much of the 
normal mouth flora and the mouth becomes colonized by 






A genetic mutation may occur during treatment and 
becomes apparent when the sensitive organisms are 
destroyed. Mutation occurs more readily with some 
antimicrobial agents than with others, and especially with 





Certain organisms may acquire resistance as a result of 
the activity of phages (bacterial viruses) which 
incorporate a resistance present in one organism and 
when released carry the resistance over to an organism 





Resistance may be transferred from one bacterial genus 
to another as a result of an exchange of extra-
chromosomal genetic particles (plasmids) during 
conjugation. This process occurs in many bacterial 
genera including most Gram-negative bacilli. It is most 
readily demonstrated among the Enterobacteriaceae. 
Resistance to a number of drugs including 
aminoglycosides, cephalosporins, chloramphenicol, 
fusidic acid, penicillins, and tetracyclines can be 
transmitted in this way. Resistance to several antibiotics 
may be transferred at one time. Resistance to other 
antibacterial agents such as sulphonamides and 
trimethoprim may also arise by transference. 
 
 
FACTORS THAT PROMOTE MICROBIAL 
RESISTANCE TO ANTIBIOTICS 
 
When antibiotics are underused, overused or misused, 
the process of antibiotic resistance is increased 
(Williams, 2000). The indiscriminate use of antibiotics, 
which promotes antibiotic resistance, results from 
patients’ demand, prescribers, drug advertisement, 





Doctors and prescribers are influenced greatly by 
patients’ demand even if they are sure of their diagnosis. 






itional doctors/practitioners are prescribing allopathic 
medicine instead of herbal medicines. To avoid being 
labeled difficult, 60% of health workers in Tanzania for 
instance, admitted to prescribing inappropriate drugs 
especially those demanded by socially influential patients 
(Muyika et al., 1991). A study in India revealed that many 
Indians believed in the efficacy of tonics and would not 
return to a doctor unless a tonic is prescribed as they 
wish. The doctors prescribe tonics to patients even when 
they are ineffective because their livelihood depends on 
the number of patients that attend their clinics (Council of 





Prescribers have different variations in the prescribing of 
antibiotics and other drugs. It has been shown that 30 to 
60% of patients receive twice or more of what is perhaps 
needed. Incorrect dosage or inappropriate prescription 
makes misuse of antibiotics common. In India, a study 
showed that over 90% of prescriptions do not have dose 
specifications (Uppal et al., 1993). Inappropriate 
prescription of antibiotics has been reported to occur for 
viral respiratory tract infections in 97% of cases in China 
(Hui et al., 1997), and 81% of cases in Ghana (Bosu et 
al., 1997). In Pakistan, there have been reports of 
inappropriate use of antibiotics for childhood diarrhoea 
where private medical practitioners were reported to 
prescribe significantly more antibiotics in 41% of 
paediatric cases than paediatricians in 36% of paediatric 
cases in the public hospitals (Nizami et al., 1996).  
Providers prescribe antibiotics too often and 
unnecessarily because of patients’ demand, lack of 
adequate knowledge or information concerning the drugs 





The pharmaceutical companies aid in promoting bacterial 
resistance to currently available antibiotics. According to 
an advert by a company, Ciprofloxacin is the appropriate 
drug of choice for a patient at risk. There was then a 
question in the advert: ‘For whom?’ This was answered 
by a small asterisk on the word ‘risk’ showed at the 
bottom of the page. For who the drug was appropriate, 
was answered in small type and they stated that it should 
be used in challenging respiratory tract infections. The 
term ‘challenging’ was never explained nor defined. This 
company ironically, claimed in the same advert to 
support the appropriate use of antibiotics (Lexchin, 
2000).  
Adverts that do not clearly explain the use of drugs, for 
whom and other needed information or that gives them in 
very small  prints  that  they  are  not  noticeable,  do  not 
support the appropriate use of drugs. In the advert  




described above, the message to doctors is that they 
should freely use it as a first line agent whenever they 
are challenged with their patients’ ailment or when they 
feel that something strange is going on. Ciprofloxacin is a 
first drug choice for some ailments but not for most 
respiratory tract infections. The use of ciprofloxacin has 
been restricted in these situations by the Australian 
Schedule of Pharmaceutical Benefits and also in some 
Canadian provinces (Lexchin, 2000). The potentials for 
drug interactions with the antacids and theophylline, the 
potential of developing bacterial resistance during 
treatment and the risk of toxicity especially in elderly 
patients who have decreased level of renal functions, are 
drawbacks to the use of these drugs in therapy. The 
fluoroquinolones are known to cause erosion of 
cartilages in the joint of immature animals. Therefore, 
they are contraindicated in the treatment of children. 
What this advert did, was to promote a drug as the first 
drug of choice, which should be reserved. They also 
promoted inappropriate use of the antibiotic that has the 
potential of leading to antibiotic resistance. 
An advertisement in the Philippines in 1994 and 1995 
promoted the use of clindamycin for upper respiratory 
tract infections and lincomycin for pharyngitis/tonsillitis. 
The most likely causative agent of these diseases is viral 
infections that cannot be treated with antibiotics. This is a 
clear case of antibiotics being advertised for conditions 
that do not require them. In 1996, researchers presented 
a group of primary care doctors with three cases, two of 
which involved infectious diseases and they asked them 
to choose between four treatment options of equal 
efficacy but they had wide varying costs. The results 
showed that the more credibility that the doctors attached 
to the information from the sales representatives, the 
higher the doctors’ cost of prescription (Caudill et al., 
1996). In many cases of inappropriate use of antibiotics, 
the doctor lack sources of objective information about the 
antibiotics. They are totally reliant on promotional 
materials from the companies with all the biases that 
they contain. In a peripheral health care in Sri Lanka in 
the mid 1980s, where multiple antibiotic therapies, 
polypharmacies and the use of mixtures of unproven 
efficacy were common, the physicians depended totally 
and were positively confident on the information from 
pharmaceutical companies (Tomson et al., 1990). 
 
 
Dispensing prescribers  
 
Many doctors and prescribers make a living from selling 
drugs and not necessarily from consultations. Many such 
doctors that earn money from dispensing drugs tend to 
prescribe more than those that do not. A study in 
Zimbabwe, for instance, showed that such doctors 
prescribed antibiotics to 58% of their patients while the 
non-dispensing prescribers, prescribed  same  antibiotics 
to 48% of their patients (Trap et al., 2000; Unpublished  
 




Study). Following the socialist reforms of China in the 
late 70s, sale of drugs became a significant source of 
income, forming part of the salaries of many health 
workers and prescribers. Subsequently, more 
polypharmacies were observed and cost of prescriptions 
increased by two to six times (Sha-Kang et al., 1998). 
Because these dispensing prescribers earn more money 
through selling high cost drugs such as the antibiotics, 
they tend to over-prescribe them. However, most 
patients are not able to afford these drugs; hence they 
end up not completing the required dosage, creating 
room for development of resistance. 
 
 
Use of antibiotics in agriculture 
 
Some antibiotics used in treatment of human infections, 
especially the enterococcal and staphylococcal types, 
are equally employed in similar infections occurring in 
plants and animals. The use of penicillin and 
tetracyclines in animal feeds increases the number of 
resistant organisms within the animal bowel and the 
existence of such organisms appear to increase the 
proportion of resistant organisms in man. The use of 
antibiotics in animal feeds was restricted in the United 
Kingdom following the adoption of recommendations of 
the report of the Swann Committee (1969). Some of the 
newly emerging resistant strains of bacteria found in 
animals can be transmitted to humans through direct 
contact with the animals in question or food/materials 
from them. Resistance to salmonella and enterococcus 
has been attributed to the use of some antibiotics in 
agriculture. Some of the factors responsible for 
development of resistance to antibiotics by animals 
include use of sub-therapeutic doses as growth 
promoters, inefficient regulatory mechanisms, poor 
training of personnels and predominance of empirical 
treatments due to limited diagnostic tools. The use of 
vancomycin in agriculture has been implicated in the 
development of vancomycin-resistant strains of 




MEASURES TO MINIMISE DRUG RESISTANCE 
 
The more frequently an antibiotic is used, the greater the 
prevalence of bacteria resistant to that agent. For 
example, neomycin-resistant staphylococci appear when 
neomycin sprays or powders are widely used. The 
resistant organisms decrease in numbers when the use 
of the antibiotic is curtailed. When a resistance factor 
carrying resistance to several agents, for example 
ampicillin, carbenicillin, streptomycin, and tetracycline, is 
present in a hospital unit the resistant organisms may not 





Antibiotics should therefore not be used unless 
specifically indicated. 
Since much antibiotic therapy is given in the absence 
of bacteriological studies in the individual patient, the 
current antibiotic sensitivity patterns of common 
organism can provide a guide to the most suitable agent. 
Early treatment should be based on antibiotics that are 
most likely to succeed in a particular case, and should be 
modified as necessary when the results of sensitivity 
tests are available. This is particularly important in 
hospitals where the majority of resistant bacteria are 
found. The pattern of resistance found among hospital 
organisms should influence the choice of antibacterials in 
general use. Periodic revision of prescribing policies is 
essential in limiting the spread of resistant organisms. In 
long-term therapy, as in tuberculosis, two or more 
antibiotics or chemotherapeutic agents of different types 
should be given at the same time to delay the 
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